Cell and Gene Therapy Market (By Therapy Type: Gene Therapy, Cell Therapy; By Application: Oncology, Genetic Disorders, Dermatology Disorders, Musculoskeletal Disorders, Others; End-Users: Hospitals, Cancer Care Centers, Wound Care Centers, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cell and Gene Therapy Market 

5.1. COVID-19 Landscape: Cell and Gene Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cell and Gene Therapy Market, By Therapy Type

8.1. Cell and Gene Therapy Market, by Therapy Type, 2022-2030

8.1.1 Gene Therapy

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Cell Therapy

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Cell and Gene Therapy Market, By Application

9.1. Cell and Gene Therapy Market, by Application, 2022-2030

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Genetic Disorders

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Dermatology Disorders

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Musculoskeletal Disorders

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Cell and Gene Therapy Market, By End-Users 

10.1. Cell and Gene Therapy Market, by End-Users, 2022-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Cancer Care Centers

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Wound Care Centers

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Cell and Gene Therapy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.1.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.2.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.3.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End-Users (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End-Users (2017-2030)

Chapter 12. Company Profiles

12.1. Gilead sciences

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Novartis

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Smith Nephew (Osiris Therapeutic)

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Amgen

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Organogenesis

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Roche (Spark Therapeutics)

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Dendreon

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Vericel

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Bristol-Myers Squibb

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Report Detail

Proceed To Buy

USD 3500
USD 7000